Please note: Sessions are run on the Zoom Webinar platform (which automatically launches when you click View Session) and all sessions are run in EDT Timezone and will be available on-demand on July 13th
| Track | Name | Speakers |
|---|---|---|
| 8:50 AM - 9:00 AM (EDT) | ||
| OCTS | KEYNOTE: Next Generation for Cell Therapies | Carl June - Perelman School of Medicine, University of Pennsylvania |
| 9:05 AM - 9:45 AM (EDT) | ||
| OCTS | EXECUTIVE PANEL: Exploring the hurdles that are in place whilst targeting solid tumors; and how to clear the route for an “off the shelf” therapy | Nick Cernese - EY Peter Emtage - Kite Pharma Inc Pascal Touchon - Atara Biotherapeutics Stefan Wildt - Takeda Pharmaceuticals |
| 9:50 AM - 10:20 AM (EDT) | ||
| OCTS | HEADLINE KEYNOTE: Unlocking the power of data and technology to deliver on the promise of cell and gene therapies | Adlai Goldberg - EY David Rhew - Microsoft Orlando Serani - Johnson & Johnson Sarah Dye - Optum |
| 10:35 AM - 10:55 AM (EDT) | ||
| Clinical & Commercialization | PRESENTATION: Clinical use of CAR-T for DLBCL | David Miklos - Stanford University |
| Natural Killer Cells | PRESENTATION:Natural Killer cells in cancer immunotherapy | Jeffrey S Miller - University of Minnesota Medical School |
| Vein to Vein | PRESENTATION:Transitioning from outsourcing to in-house manufacturing facilities and accessing cell therapy manufacturing models | Knut Niss - Mustang Bio |
| CAR-T R&D | PRESENTATION: Cartitude-1 Study with Updates in Toxicity & Management | Deepu Madduri - The Mount Sinai Hospital |
| 11:00 AM - 11:20 AM (EDT) | ||
| Clinical & Commercialization | PRESENTATION: Non-viral technologies for development and manufacture of next generation cell therapies | Shirley O'Dea - Avectas |
| CAR-T R&D | PRESENTATION: Technology (and) Innovation to support the global scaleup challenges on the horizon: | Steven Lynum - PHC Corporation Carl Radosevich - PHC Corporation |
| 11:35 AM - 11:55 AM (EDT) | ||
| Vein to Vein | PRESENTATION: Guidelines for cell characterisation and cell function | John Elliot - NIST |
| Clinical & Commercialization | PRESENTATION: Large B cell lymphoma long term safety trials | Caron Jacobson - Dana Faber Cancer Institute |
| Natural Killer Cells | PRESENTATION: Maximising the therapeutic effect of allogeneic natural killer cells | James Trager - Nkarta Ivan Chan - Nkarta |
| CAR-T R&D | PRESENTATION: Using Red Cell Therapeutics to Enhance Antitumor Immune Reponses | Christina Coughlin - Rubius Therapeutic |
| 12:00 PM - 12:20 PM (EDT) | ||
| OCTS | PRESENTATION: Scale-Out of Commercially Viable Autologous CAR T Cell Manufacturing | Fred Koller - Miltenyi Biotec, Inc. |
| Track | Name | Speakers |
|---|---|---|
| 8:55 AM - 9:15 AM (EDT) | ||
| OCTS | PRESENTATION: Development of autologous cellular immunotherapies optimizing personalized, tumor directer TILs | Maria Fardis - Iovance Biotherapeutics |
| 9:30 AM - 9:50 AM (EDT) | ||
| Clinical & Commercialization | PRESENTATION: Development of TCR T cell Therapies for Treatment of Solid Tumors | Paul Stead - Adaptimmune |
| Vein to Vein | PRESENTATION: CMC project management for cell and gene therpaies | Seshu Tyagarajan - Novartis Pharmaceuticals Corporation Rachit Jain - Werum IT Solutions America |
| CAR-T R&D | PRESENTATION: Enhancing CAR-T with small molecules to regulate for enhanced activity against solid tumor | Steve Shamah - Obsidian Therapeutics |
| 9:55 AM - 10:15 AM (EDT) | ||
| Vein to Vein | PRESENTATION: Next Generation Workforce Development for Cell Therapy Manufacturing | Haro Hartounian - BioPharma Innovation |
| Clinical & Commercialization | PRESENTATION: Artificial intelligence for tumor specific neoantigen identification | Matt Davis - Gritstone Oncology |
| 10:20 AM - 10:50 AM (EDT) | ||
| Clinical & Commercialization | PRESENTATION: Lentiviral vectors: towards more cost-effective, scalable and regulatory-compliance processes. | Juan Carlos Ramirez - VIVEbiotech |
| CAR-T R&D | PRESENTATION: Molecular Characterization for CAR-T Cell Therapy: A Step Toward Standardization with the nCounter® CAR-T Characterization Panel | Erin Piazza - NanoString |
| 10:55 AM - 11:20 AM (EDT) | ||
| OCTS | Interactive Focused Round Tables 2: Development of Functional Lymphocytes from Human Pluripotent Stem Cells | Dan Kaufman - UCSD |
| OCTS | Interactive Focused Round Tables 1: Cell Homing to Target Solid Tumors | Robert Kochl - Kings College London |
| OCTS | Interactive Focused Round Tables 3: Targeting glioblastoma through the use of cell therapies | Andrew Spiegel - Global Colon Cancer Association |
| 11:25 AM - 11:45 AM (EDT) | ||
| CAR-T R&D | PRESENTATION: Fusion Proteins to bridge CAR19 T cell and tumor cells | Paul Rennert - Aleta Biotherapeutics |
| 11:50 AM - 12:10 PM (EDT) | ||
| OCTS | PRESENTATION: Vd1 Gammadelta T Cells | Alice Brown - GammaDelta Therapeutics |
| Track | Name | Speakers |
|---|---|---|
| 9:05 AM - 9:40 AM (EDT) | ||
| OCTS | PRESENTATION: Challenges of Vector Production in Support of Phase I Clinical Trials | Steven Feldman - Stanford Center for Cancer Cell Therapy |
| 9:45 AM - 10:20 AM (EDT) | ||
| OCTS | PRESENTATION: Best practice REMS development | Larissa Lapteva - FDA |
| 10:25 AM - 10:45 AM (EDT) | ||
| OCTS | PRESENTATION: Adoptive cell therapy using engineered TAC T-cells to invade solid tumors | Paul Lammers - Triumvira Immunologics |
| 10:50 AM - 11:10 AM (EDT) | ||
| OCTS | PRESENTATION: TRuC®-T Cells: Harnessing The Full T Cell Receptor without HLA Restriction for Cancer Therapy | Robert Hofmeister - TCR2 |
| 11:25 AM - 11:45 AM (EDT) | ||
| OCTS | PRESENTATION: Digital Solution for Cell and Gene Therapy with Lessons learned | Ryan Hamilton - Werum IT Rachit Jain - Werum IT Solutions America |
| 11:50 AM - 12:20 PM (EDT) | ||
| OCTS | PANEL: Allogeneic Therapies | Peggy Sotiropoulou - Celyad Oncology Alan Trounson - Cartherics Pty Ltd |
| 1:00 PM - 6:00 PM (EDT) | ||
| OCTS | Dedicated Networking Time - until 6:30pm | |